GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

By reclassifying a chemical drug under a different name and label, GlaxoSmithKline avoided rebate obligations tied to the Flovent price inflation, the lawsuit says. "It raised the price so much ...

Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

GSK has previously said that the broader label in first-line endometrial cancer will be the key to pushing annual sales of Jemperli into blockbuster territory. The drug generated £188 million ($ ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

GSK looks like it is starting to show the benefit ... the latter way ahead of analyst expectations thanks to a wider-than-expected label granted by the FDA last September.

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...